Skip to main content
. 2021 Mar 3;11:554503. doi: 10.3389/fonc.2021.554503

Table 3.

Univariable and multivariable analyses for risk factors of relapse and survival.

Parameters Relapse Overall survival Leukemia-free survival GVHD-free/relapse-free survival (GRFS)
Univariable P value Multivariable P value;HR (95% CI) Univariable P value Multivariable P value;HR (95% CI) Univariable P value Multivariable P value;
HR (95% CI)
Univariable P value Multivariable P value;
HR (95% CI)
Female vs. male 0.160 0.866 0.627 0.283
Patient age
≥29 vs. <29 years (median)
0.207 0.133 0.172 0.111
Disease category
AML vs. ALL vs. ABL
0.644 0.759 0.657 0.736
Genetic status
Other vs. unfavorable
0.201 0.451 0.318 0.253
BM blasts on day 0
≥3% vs. <3% (median)
*0.001 *0.001; 4.340
(2.359–7.987)
*0.001 *0.001; 2.861
(1.744–4.693)
*0.001 *0.001; 3.016
(1.843–4.936)
*0.001 *0.001; 3.656
(2.328–5.743)
Transplant modality
HID vs. MSD/MUD
*0.040 *0.038; 0.476
(0.237–0.959)
0.125 0.061 0.076; 0.610
(0.354–1.053)
0.222
Strategy of pDLI
modified vs. previous
0.456 0.863 0.666 *0.044 *0.010; 0.459
(0.292–0.722)
Number of pDLI
0 vs. 1 vs. >1
0.552 0.514 0.375 0.776
aGVHD
II–IV vs. 0–I
0.359 * 0.012 0.061; 1.604
(0.978–2.630)
*0.023 0.096; 1.517
(0.928–2.480)
*0.009 *0.020; 1.679
(1.086–2.596)
cGVHD vs. No cGVHD *0.030 *0.041; 0.526
(0.294–0.939)
*0.002 *0.002; 0.454
(0.279–0.739)
*0.005 *0.010; 0.524
(0.321–0.855)
0.677

AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; ABL, acute biphenotypic leukemia; BM, bone marrow; HID, HLA-haploidentical related donor; MSD, HLA-matched sibling donor; MUD, HLA-matched unrelated donor; pDLI, prophylactic donor lymphocyte infusion; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; HR, hazard risk; CI, confidence interval; *P < 0.05.